Citruslabs
Las Vegas, Nevada, 89118, United States
NCT Number: NCT07700745
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.
This study is active but is not currently recruiting participants.
18 year–65 year
All sexes
Interventional
Not applicable
Las Vegas, Nevada, 89118, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.
Time frame: Baseline to Week 4
Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 4
Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 4
Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 4
Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 4
Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform
Time frame: Baseline to Week 4
Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire
Time frame: Baseline to Week 4
Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire
Time frame: Baseline and Week 4
Independent expert dermatologist grading of change in erythema from standardized photographs of a designated affected body area
Time frame: Baseline and Week 4
Independent expert dermatologist grading of change in scaling from standardized photographs of a designated affected body area
Rejuvaskin
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05559359
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT01782703
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Chicago, Illinois, United States
View Trial DetailsNCT07011706
AD, Atopic
Phoenix, Arizona, United States
View Trial DetailsNCT03742414
Atopic Dermatitis, Atopic Dermatitis Eczema
Palo Alto, California, United States
View Trial Details